scholarly journals TLR signaling inhibitor, phenylmethimazole, in combination with tamoxifen inhibits human breast cancer cell viability and migration

Oncotarget ◽  
2016 ◽  
Vol 8 (69) ◽  
pp. 113295-113302 ◽  
Author(s):  
Anthony L. Schwartz ◽  
Eric Dickerson ◽  
Nilesh Dagia ◽  
Ramiro Malgor ◽  
Kelly D. McCall
2022 ◽  
Vol 124 (1) ◽  
pp. 151832
Author(s):  
Aida Karimian ◽  
Fereshteh Mir Mohammadrezaei ◽  
Akbar Hajizadeh Moghadam ◽  
Mohammad Hadi Bahadori ◽  
Marjan Ghorbani-Anarkooli ◽  
...  

2016 ◽  
Vol 78 (3) ◽  
Author(s):  
Aishah Badruzzaman ◽  
Noriah Bidin ◽  
Siti Pauliena Mohd Bohari

This study compared the effects of different sources of laser phototherapy on the cell viability of the in vitro human breast cancer cell lines. Laser phototherapy is used in the breast cancer clinical treatment, despite the limited safety information of laser irradiation effect on the cancer cell behavior. This study contributed on the development of guidelines for safer laser usage in treating breast cancer and minimising the possibility of activating postmastectomy lymphedema. Cancer cell viability and morphology were studied in this research. Human breast cancer (MDA-MB-231) cell lines were cultured for 24 hours in CO2 incubator and irradiated with different laser sources and number of pulse. The viability of cancer cells were assessed by MTT assay 24 hours after laser irradiation. The result showed that MDA-MB-231 cell viability increased after being irradiated by excimer 248 nm laser. However, the cancer cell viability slightly decreased after irradiation by both Nd:YAG 1064 and 532 nm. Although certain doses of laser may affect the MDA-MB-231 cell viability, additional laser exposures had nearly no effect. The research shows that Nd:YAG 1064 nm more effective in lowering cancer cell survivability than 532 nm and 248 nm. Further in vivo studies are needed for better understanding on the mechanism of laser-tissue interaction and improve the laser usage safety in photothermal therapy. 


2017 ◽  
Vol 14 (1) ◽  
pp. 1054-1060 ◽  
Author(s):  
Taciane Macedo ◽  
Renato J. Silva-Oliveira ◽  
Viviane A.O. Silva ◽  
Daniel O. Vidal ◽  
Adriane F. Evangelista ◽  
...  

2008 ◽  
Vol 197 (3) ◽  
pp. 517-529 ◽  
Author(s):  
Sanda Raulic ◽  
Yudith Ramos-Valdes ◽  
Gabriel E DiMattia

Stanniocalcin 1 (STC1) and STC2 are secreted, homodimeric glycoproteins that share 30% amino acid sequence identity. Breast tumour gene profiling studies have demonstrated significantly upregulated STC2 expression in hormone-responsive positive breast tumours; therefore, the purpose of this study was to investigate STC2 hormonal regulation and function in breast cancer cells. Here we report that STC2 is expressed in a number of human breast cancer cell lines, regardless of their oestrogen (E2) and progesterone (P4) receptor status, and its expression is readily detectable in human and mouse mammary gland tumours. Besides E2, retinoic acid (RA) and P4 play an important role in the regulation of STC2 expression, not only in MCF-7 but also in other breast cancer and non-breast cell lines. The expression of the related hormone, STC1, is not affected by the above hormones in breast and endometrial cancer cell lines implying a fundamental difference in regulation in cancer cell lines. The induction of STC2 expression by E2 and RA occurs at the transcriptional level but through intermediary transcription factors. The STC2 proximal promoter region is not responsible for hormonal induction, but exhibits a high basal transcriptional activity. Constitutive STC2 expression in human breast cancer cell lines resulted in significant impairment of cell growth, migration and cell viability after serum withdrawal. In conclusion, STC2 is a downstream target of E2, P4 and RA signalling pathways. In hormone receptor negative cell lines it can function in a paracrine/autocrine fashion to reduce cell proliferation.


Sign in / Sign up

Export Citation Format

Share Document